SHANGHAI, China, June 3, 2026
Antengene has announced the first preclinical data for ATG-207, its investigational αCD3-TGF-β bifunctional fusion protein, highlighting a promising new approach for the treatment of T cell-mediated autoimmune diseases. The data will be presented at the European Congress of Rheumatology (EULAR 2026) in London and marks the first public disclosure of Antengene’s autoimmune disease research program. Designed to address one of the most significant challenges in autoimmune medicine—the inability to establish long-term immune tolerance—ATG-207 combines CD3-mediated T-cell modulation with TGFβRIII-biased TGF-β activity to selectively suppress pathogenic immune responses while promoting regulatory T-cell function. The preclinical findings position the candidate as a potentially differentiated immunotherapy capable of restoring immune balance without triggering excessive inflammatory responses, an important limitation of many current treatment approaches.
Novel Dual-Mechanism Approach Targets Immune Tolerance
Autoimmune diseases driven by dysregulated T-cell activity continue to represent a major unmet medical need worldwide. Existing therapies frequently focus on suppressing inflammation but may not adequately eliminate pathogenic effector T cells or restore durable immune tolerance. ATG-207 was specifically engineered to address these challenges through a unique dual-mechanism design. The therapy combines targeted CD3 receptor engagement with localized TGF-β signaling biased toward TGFβRIII, enabling selective immune modulation rather than broad immunosuppression.
According to Antengene, this approach aims to reduce harmful immune activation while encouraging the development of regulatory T cells (Tregs) that play a critical role in maintaining immune homeostasis. By promoting immune tolerance at the cellular level, ATG-207 may offer a fundamentally different strategy for managing chronic autoimmune disorders compared with conventional anti-inflammatory treatments.
Preclinical Studies Demonstrate Strong Therapeutic Potential
Advertisement
The preclinical research presented at EULAR evaluated multiple biological characteristics of ATG-207, including receptor binding, T-cell receptor modulation, cytokine release profiles, regulatory T-cell induction, and therapeutic activity in autoimmune disease models. Results demonstrated that the molecule exhibited preferential binding to TGFβRIII, successfully downregulated surface T-cell receptor expression, and induced regulatory T-cell expansion in laboratory studies. In vivo evaluation using a surrogate molecule in an experimental autoimmune encephalomyelitis (EAE) model, a widely accepted model for autoimmune neurological disorders, demonstrated meaningful therapeutic activity.
Importantly, researchers observed that ATG-207 generated substantially lower levels of pro-inflammatory cytokine release compared with an unbiased αCD3-TGF-β fusion protein control. Reduced cytokine release is considered a critical safety advantage because excessive cytokine production can contribute to treatment-related toxicities and limit therapeutic utility. These findings suggest that ATG-207 may be capable of delivering potent immune regulation while maintaining a favorable safety profile.
Expanding Antengene’s Presence in Autoimmune Disease Innovation
The ATG-207 program represents a significant expansion of Antengene’s research portfolio beyond oncology and hematologic malignancies into the rapidly growing autoimmune disease sector. The company believes its proprietary scientific platforms and expertise in immune modulation can be leveraged to develop next-generation therapies for diseases characterized by chronic immune dysfunction. As autoimmune disorders continue to affect millions of patients globally, there remains strong demand for treatments capable of achieving durable disease control without the limitations associated with long-term immunosuppression.
The promising preclinical profile of ATG-207 supports further development and reinforces Antengene’s commitment to discovering first-in-class and best-in-class therapies for serious diseases with significant unmet medical needs. With the first data now entering the scientific spotlight at EULAR 2026, the program may emerge as an important addition to the evolving landscape of immune tolerance-based therapies and could potentially open new opportunities for treating a broad range of autoimmune conditions in the future.
Source: Antengene press release
